22 results on '"MAY JR"'
Search Results
2. CO33 A Systematic Literature Review (SLR) of Comparative Efficacy Measures in Randomized Controlled Trials (RCTS) of Adjuvant Treatment in Localized Renal Cell Carcinoma (RCC)
3. EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
4. POSB302 Assessing the Viability of a Surrogacy Relationship between Disease-Free Survival (DFS) and Overall Survival (OS) for the Patients in Clinical Trials for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Following Radical Cystectomy.
5. POSC321 Estimating Long-Term Survivorship Rates for Previously Untreated Intermediate or Poor (I/P) Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI): Analyses from the CheckMate 214 Trial
6. POSC6 Efficacy and Safety Results from Real-World Studies Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR)
7. POSB53 Healthcare Resource Utilization (HCRU) and Cost Studies in Patients Receiving First-Line (1L) Therapy for Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)
8. POSA150 Cost-Effectiveness Analysis of First-Line (1L) Systemic Treatments in Advanced Renal Cell Carcinoma (aRCC) in France
9. POSB3 Multidimensional Treatment Effect Network Meta-Analysis to Estimate Survival of Therapies for Patients with First-Line (1L) Advanced or Metastatic Renal Cell Carcinoma (ARCC) in France
10. POSB8 Efficacy and Safety Results from Randomized Controlled Trials (RCTS) Evaluating Adjuvant Treatment after Radical Resection (RR) of Muscle Invasive Urothelial Carcinoma (MIUC): A Systematic Literature Review (SLR)
11. POSA320 Development of a Decision Algorithm for Fractional Polynomial (FP) Model Selection in Network Meta-Analysis (NMA): Why Statistical Fit Criteria Alone Is Not Enough
12. POSC56 Healthcare Resource Use (HCRU), Cost Inputs, and Cost-Effectiveness Analysis (CEA) for Patients with Muscle Invasive Urothelial Carcinoma (MIUC) Treated with Radical Resection (RR): A Systematic Literature Review (SLR)
13. POSA58 Cost-Effectiveness (CE) Analyses for First-Line (1L) Treatment of Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)
14. POSB340 Availability of Published Health-Related Quality of Life (HRQOL) Data for Patients Receiving First-Line (1L) Treatment for Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)
15. POSA342 Reported Utilities and Health-Related Quality of Life (HRQOL) Data for Patients with Muscle Invasive Urothelial Carcinoma (MIUC) Treated with Radical Resection (RR): A Systematic Literature Review (SLR)
16. POSB283 Approaches for Cost-Effectiveness Analyses in Adjuvant Oncology Indications and Their Acceptability By HTA Authorities
17. POSA7 Clinical and Health-Related Quality of Life (HRQOL) Outcomes from Interventional Studies in First-Line (1L) Advanced or Metastatic Urothelial Cancer (MUC): A Systematic Literature Review (SLR)
18. POSA35 Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up Data from CheckMate 214
19. Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for The Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Metastatic Breast Cancer from A US Private Third-Party Payer Perspective
20. Budget Impact of Ribociclib Plus Letrozole For The Treatment of Post-Menopausal Women With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2- Negative (HER2-) Advanced or Metastatic Breast Cancer From A US Private Third-Party Payer Perspective
21. PCN133 - Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for The Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Metastatic Breast Cancer from A US Private Third-Party Payer Perspective
22. PCN62 - Budget Impact of Ribociclib Plus Letrozole For The Treatment of Post-Menopausal Women With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2- Negative (HER2-) Advanced or Metastatic Breast Cancer From A US Private Third-Party Payer Perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.